Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ADC Therapeutics SA
< Previous
1
2
3
Next >
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 29, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 13, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces CEO Transition
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
May 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
April 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
February 24, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
February 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
February 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in Guggenheim Oncology Conference
February 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
January 18, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
November 04, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 02, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
October 29, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
October 27, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
September 27, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
September 13, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
September 09, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Medical Leadership Transition
September 03, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
August 26, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 03, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
July 28, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
June 22, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
June 18, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
June 11, 2021
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.